Recursion Pharmaceuticals reported a quarterly loss of $0.22 per share, beating the Zacks Consensus Estimate for a $0.30 loss and improving from a $0.50 loss a year ago. The narrower-than-expected loss suggests modest progress in earnings performance. The release is likely to be stock-specific rather than sector-wide.
Recursion Pharmaceuticals reported a quarterly loss of $0.22 per share, beating the Zacks Consensus Estimate for a $0.30 loss and improving from a $0.50 loss a year ago. The narrower-than-expected loss suggests modest progress in earnings performance. The release is likely to be stock-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
